Kymriah Received Accelerated FDA Approval for Relapsed or Refractory Follicular Lymphoma

JHOP - June 2022 Vol 12, No 3 - FDA Oncology Update, Lymphoma, CAR T-Cell Therapy
Download PDF

On May 27, 2022, the FDA accelerated the approval of a new indication for the CD19-directed CAR T-cell therapy tisagenlecleucel (Kymriah; Novartis) for adults with relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. The FDA granted this indication an orphan drug designation.

“The approval of Kymriah offers patients with relapsed or refractory follicular lymphoma a new treatment option and new hope for improving patient outcomes,” Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation, said in a press release. “Having this single infusion treatment option helps to transform the way healthcare providers approach this type of blood cancer.”

The approval was based on the ELARA study, a multicenter, single-arm, open-label clinical trial of adults with relapsed or refractory follicular lymphoma within 6 months after completion of ≥2 lines of systemic therapy (including an anti-CD20 antibody and an alkylating agent) or relapsed after autologous hematopoietic stem-cell transplant.

The main efficacy measures were overall response rate (ORR) and duration of response (DOR). Among the 90 patients in the primary efficacy analysis, the ORR was 86% (95% confidence interval [CI], 77-92), including 68% complete responses. At 9 months, the median DOR was not reached, and 75% of those with a response were still responding to the CAR T-cell therapy. For the 98 patients who underwent leukapheresis, the ORR was 86% (95% CI, 77-92), including 67% complete responses.

The most common (>20%) adverse reactions were cytokine-release syndrome, infection, fatigue, musculoskeletal pain, headache, and diarrhea.

Continued approval for this indication may be contingent on verification of the clinical benefit in confirmatory trial(s).

Related Items
FDA-Approved Nirogacestat Demonstrates Improved Patient Outcomes in Desmoid Tumor Management
Web Exclusives published on February 12, 2024 in FDA Oncology Update
Iwilfin FDA Approved for Adults and Pediatric Patients with High-Risk Neuroblastoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Welireg Now FDA Approved for Patients with Advanced Renal Cell Carcinoma
Web Exclusives published on January 17, 2024 in FDA Oncology Update
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of Advanced Gastroesophageal Junction Adenocarcinoma
Web Exclusives published on December 19, 2023 in FDA Oncology Update
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation
Web Exclusives published on December 18, 2023 in FDA Oncology Update
Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form
JHOP - December 2023 Vol 13, No 6 published on December 6, 2023 in FDA Oncology Update
FDA Authorizes Updated COVID-19 Vaccine Formulations for Better Protection Against Current Variants
JHOP - December 2023 Vol 13, No 6 published on November 17, 2023 in FDA Oncology Update
Bosulif Now FDA Approved for Pediatric Patients With Chronic Myelogenous Leukemia
JHOP - December 2023 Vol 13, No 6 published on November 3, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: